ARTICLE
12 March 2020

March Issue Of Bio/Pharma Beat Now Available!

SP
Squire Patton Boggs LLP

Contributor

Squire Patton Boggs LLP
Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions.
United States Intellectual Property

Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month's issue covers relevant news from February 2020, including:

  • A Federal Circuit decision applies a presumption that an express license to a patent includes an implied license to its continuations.
  • A district court finds after trial that defendants' obviousness theory had "major defects and does not come close to meeting the clear and convincing standard."
  • A district court holds that dedication-disclaimer does not apply where the allegedly dedicated subject matter is found in another claim in the same patent.
  • The FDA and FTC announce a collaboration "to advance competition in the biologic marketplace."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More